https://ift.tt/EC0Dfb2 New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis from Sanofi - Avent…
Read morehttps://ift.tt/A0ToFrW from Sanofi - Aventis Groupe https://ift.tt/QMy8utp via IFTTT
Read morehttps://ift.tt/MkUtvnu New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis from …
Read morehttps://ift.tt/7IHisUh from Sanofi - Aventis Groupe https://ift.tt/z2ouJMf via IFTTT
Read morehttps://ift.tt/5IzSWUl from Sanofi - Aventis Groupe https://ift.tt/2LMWYdk via IFTTT
Read morehttps://ift.tt/b4Tra1I from Sanofi - Aventis Groupe https://ift.tt/RyPeoAn via IFTTT
Read morehttps://ift.tt/n6MIarl Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation from Sanofi - Aventis Grou…
Read more